<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859283</url>
  </required_header>
  <id_info>
    <org_study_id>TKADEX</org_study_id>
    <nct_id>NCT04859283</nct_id>
  </id_info>
  <brief_title>Premedication With Intranasal Dexmedetomidine in Sedation of Patients Undergoing Total Knee Arthroplasty</brief_title>
  <acronym>TKADEX</acronym>
  <official_title>Premedication With Intranasal Dexmedetomidine in Sedation of Patients Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to find out if preoperatively given dexmedetomidine is effective analgesic&#xD;
      adjuvant for treating postoperative pain in patients undergoing elective total knee&#xD;
      arthroplasty (TKA). Another aim is to determine if premedication with intranasal&#xD;
      dexmedetomidine could provide sufficient sedation to alleviate anxiety during TKA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing total knee arthroplasty (TKA) under spinal anesthesia often request&#xD;
      sedation to alleviate anxiety. Dexmedetomidine may be ideally suited to provide sedation&#xD;
      during surgery as it offers sedation and analgesia without causing significant respiratory&#xD;
      depression. Furthermore, dexmedetomidine has beneficial synergistic interactions with opioids&#xD;
      and sedative drugs.&#xD;
&#xD;
      Altogether 80 patients scheduled for elective unilateral TKA under spinal anesthesia will be&#xD;
      included in the prospective, randomized and controlled parallel-group study. Patients will be&#xD;
      randomized into two groups, forty patients in each group. All patients will receive&#xD;
      preoperatively 1000 mg of oral paracetamol as premedication. One group receives a single&#xD;
      bolus dose of intranasal 1 ug/kg dexmedetomidine (DEX group) and the other group receives&#xD;
      euvolemic dose (10 µL/kg) of saline (PLACEBO-group).&#xD;
&#xD;
      Spinal anesthesia will be performed using bupivacaine (5 mg/mL) using 2.0-2.5 mL dose, the&#xD;
      amount depending on the clinical judgement of the anesthesiologist responsible for the&#xD;
      patient. If patient needs additional analgesic after spinal anesthesia, 50 µg dose of&#xD;
      intravenous fentanyl or 3-5 mg of intravenous midazolam may be administered intraoperatively.&#xD;
&#xD;
      Postoperative pain management in the surgical ward includes oral paracetamol 1000 mg every 8&#xD;
      hours, and from the first postoperative day onwards patients receive oral&#xD;
      naproxen/esomeprazole 500/20 mg twice a day. Oral oxycodone (5-10 mg) will be used, if the&#xD;
      pain (measured with visual rating scale, VAS, min 0, max 100, higher scores mean worse&#xD;
      outcome) is moderate or intense (VAS&gt;30) after paracetamol and naproxen.&#xD;
&#xD;
      Postoperative pain (VAS) and opioid consumption (mg) will be measured and analysed together&#xD;
      with intraoperative sedative used (mg, midazolam and/or fentanyl allowed).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in visual rating scale (VAS 0-100 mm, min 0, max 100, higher score means worse outcome)</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients with visual rating scale value under 30 mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intraoperative sedatives (mg) administered</measure>
    <time_frame>From anesthesia induction to the end of surgery.</time_frame>
    <description>Change from baseline midazolam and fentanyl consumption (mg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in opioid consumption (mg) postoperatively</measure>
    <time_frame>24 hours</time_frame>
    <description>Change from baseline opioid consumption (mg) postoperatively at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change (mmHg) in hemodynamic parameter (blood pressure)</measure>
    <time_frame>24 hours</time_frame>
    <description>More than 30% change from the baseline in the blood pressure (measured in mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (%) in respiratory parameter (peripheral oxygen saturation, SpO2)</measure>
    <time_frame>24 hours</time_frame>
    <description>More than 10% change from the baseline in the SpO2 (measured %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients with adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>DEX-group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intranasal dexmedetomidine 1 µg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO-group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intranasal saline 10 µL/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device</description>
    <arm_group_label>DEX-group</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.</description>
    <arm_group_label>PLACEBO-group</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is scheduled for elective unilateral total knee arthroplasty (TKA) under&#xD;
             spinal anesthesia&#xD;
&#xD;
          2. Fluent skills in finnish language (to understand the given information and to be able&#xD;
             to give informed consent and communicate with the study personnel)&#xD;
&#xD;
          3. Age between 35 and 80 years&#xD;
&#xD;
          4. Weight between 50 and 100 kg&#xD;
&#xD;
          5. American Society of Anesthesiologists status 1-3&#xD;
&#xD;
          6. Written informed consent from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A previous history of intolerance to the study drug or related compounds and additives&#xD;
&#xD;
          2. Disease or condition affecting patient's ability to give written informed consent&#xD;
&#xD;
          3. Existing or recent disease possible affecting absorption, distribution, metabolism,&#xD;
             excretion or response to the study drug&#xD;
&#xD;
          4. History of severe cardiac disease (valvular insufficiency, severe left ventricular&#xD;
             dysfunction) or abnormal ECG rhythm (bradycardia &lt; 50/min, 2nd or 3rd degree&#xD;
             atrioventricular-block, pacemaker)&#xD;
&#xD;
          5. Preoperative systolic blood pressure &lt;110 mmHg&#xD;
&#xD;
          6. Chronic use of strong opioids, pregabalin, gabapentin, amitriptyline or duloxetine&#xD;
&#xD;
          7. Participation in any other study concomitantly or within one month prior to the entry&#xD;
             into this study&#xD;
&#xD;
          8. Clinically significant abnormal findings in physical examination or laboratory&#xD;
             screening&#xD;
&#xD;
          9. Pregnancy or breastfeeding&#xD;
&#xD;
         10. Use of any drugs known to cause enzyme induction or inhibition for a period of 30 days&#xD;
             prior to the study, use of any natural products (including grapefruit products) for at&#xD;
             least 14 days prior to the study and caffeine containing products for at least 24&#xD;
             hours prior to the study. The use of regular doses of paracetamol is allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suvi-Maria Tiainen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital, University of Turku</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suvi-Maria Tiainen, MD</last_name>
    <phone>+358443383510</phone>
    <email>suvi-maria.seppanen@fimnet.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Panu Uusalo, MD,PhD</last_name>
    <email>panu.uusalo@tyks.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital and University of Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Teijo Saari, MD, PhD</last_name>
      <email>teisaa@utu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tuula Manner, MD, PhD</last_name>
      <email>tuula.manner@tyks.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Teijo Saari, MD, PhD</investigator_full_name>
    <investigator_title>Professor and Head Physician</investigator_title>
  </responsible_party>
  <keyword>intranasal</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>multimodal analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

